RxDoctor Payments Data

Laura Eslinger

Adult Health · Ankeny, IANPI 1760840243

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $597 and has fallen 95.9% since, to $25 in 2025.

$760in general payments, 2019–2025

Across 36 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$176
  • Novo Nordisk$147
  • AstraZeneca$141
  • Abbott$73
  • Sanofi-aventis U.S. LLC$64
  • Boehringer Ingelheim$46
  • plus $114 from 5 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$760 in reported general payments places this provider in the 80th percentile of 77 adult health providers in Iowa.

See all adult health providers in Iowa

Medicare billing

Part B allowed, 2024
$12,274
Medicare patients
54
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$17,157
ByettaExenatide12$10,231
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,609
Bupropion XlBupropion Hcl19$561
Gabapentin37$508
Duloxetine Hcl34$435
Tramadol Hcl18$412
Levothyroxine Sodium45$359
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$357
Atorvastatin Calcium45$313
Omeprazole20$276
Losartan Potassium30$255
Ropinirole Hcl12$175
Lisinopril31$152
Hydroxyzine Hcl11$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$17,15714 claims
AstraZenecaByetta$141$10,23112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 adult health providers in Iowa.

Other adult health in Ankeny

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →